POSSIBILITY OF BONE METABOLISM MODULATOR (STRONTIUM RANELATE) USAGE FOR THE TREATMENT OF WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS AND ARTERIAL HYPERTENSION

• Main Authors: N. J. Hozjainova (Author), V. M. Tsareva (Author), T. V. Brook (Author), M. S. Bezaltynnyh (Author)
• Format: Book
• Published: Столичная издательская компания, 2016-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1819-6446; 2225-3653; 10.1234/1819-6446-2009-2-18-21
• Keywords: стронция ранелат; постменопаузальный остеопороз; артериальная гипертония; сердечно-сосудистое ремоделирование; Therapeutics. Pharmacology; RM1-950; Diseases of the circulatory (Cardiovascular) system; RC666-701
• Source: Рациональная фармакотерапия в кардиологии, Vol 5, Iss 2, Pp 18-21 (2016)

<p><strong>Aim.</strong> To study effect of the bone metabolism modulator strontium ranelate on bone mineral density (BMD) and to evaluate it pleiotropic effects on cardiovascular remodeling in women with postmenopausal osteoporosis (PO) and a arterial hypertension (HT).</p><p><strong>Material and methods.</strong> 45 women with PO, HT (1-2 stage) and medium/high cardiovascular risk were included in the study. 23 patients of the main group received strontium ranelate 2 g once daily additionally to antihypertensive and calcium replacement therapies. Before therapy and after 10 months MBD was evaluated by dual-energy x-ray absorbtiometry (DEXA) with usage of peripheral densitometer. Strontium ranelate effects on carotid intima-media thickness (duplex scanning) and morphofunctional cardiac indices (echocardiography) also were assessed.</p><p><strong>Results.</strong> Strontium ranelate therapy in patients with PO and HT leads to BMD rising and retardation of cardiovascular remodeling.</p><p><strong>Conclusion.</strong> Strontium ranelate is effective antiosteoporotic drug with positive influence on morphofunctional cardiac indices and carotid intima-media thickness. </p>